Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01444651 · ClinicalTrials.gov registry record · Phase 3
A Trial of Tadalafil and Glycemic Traits
A Phase 3 study of Obesity and Cardiovascular Disease, sponsored by Thomas J. Wang, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT01444651 is a Phase 3 study of Obesity and Cardiovascular Disease that has completed, run by Thomas J. Wang, MD. The registered enrollment target is 73 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01444651, a Phase 3 study of Obesity and Cardiovascular Disease, has completed, sponsored by Thomas J. Wang, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if tadalafil can help overweight and obese people metabolize blood sugar more efficiently. The investigators also want to find out if 20 mg/day of tadalafil for 3 months is safe to take without causing too many side effects. The investigators are plan to enroll 100 subjects at Massachusetts General Hospital (MGH).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tadalafil
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01444651
The ClinicalTrials.gov registry entry for NCT01444651 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The listed sponsor is Thomas J. Wang, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01444651 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01444651 about?
NCT01444651 is a clinical study titled "A Trial of Tadalafil and Glycemic Traits". The purpose of this study is to find out if tadalafil can help overweight and obese people metabolize blood sugar more efficiently. The investigators also want to find out if 20 mg/day of tadalafil for 3 months is safe to take without causing too many side effects. The investigators are plan to enro...
What is the current status of trial NCT01444651?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2011-08. Estimated completion is 2013-03.
What conditions does trial NCT01444651 study?
This clinical trial studies the following conditions: Obesity, Cardiovascular Disease, Insulin Resistance, Glucose Intolerance.
What interventions are being tested in trial NCT01444651?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT01444651?
This trial is sponsored by Thomas J. Wang, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01444651 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.